check out this post and the date on it and then check out IDIX CHART and where the stock was trading on that day, it looks like the news started to get out right about that time frame. knowledge is power, it just has to be found and acted upon in time.
Janice D. Says:
March 23rd, 2006 at 5:37 pm
Okay, they are reducing the dosage in the trials. Evidently, even though the viral load response has been nothing short of extraordinary for those on 800 mg. of NM283, they feel confident that a lower dose (400 or even 200 mg) will be sufficient to do the job, and with a much lower rate of gastro-intestinal problems. Interestingly, the rate of of GI problems was not huge, and most people that had them only experienced them for a short period of time. I guess that’s what a IIb trial is all about: find the optimal dosage with the least side effects. Otherwise, the drug appears very safe, and also incredibly effective. We’ll beat this virus with NM283, mark my words!
